Qualigen Therapeutics (QLGN) Competitors $3.51 -0.13 (-3.60%) As of 12:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QLGN vs. NEUP, PRTG, FLGC, AIMD, TLPH, CTXR, GELS, NXTC, TSBX, and APREShould you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include Neuphoria Therapeutics Inc. - Common Stock (NEUP), Portage Biotech (PRTG), Flora Growth (FLGC), Ainos (AIMD), Talphera (TLPH), Citius Pharmaceuticals (CTXR), Gelteq (GELS), NextCure (NXTC), Turnstone Biologics (TSBX), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry. Qualigen Therapeutics vs. Neuphoria Therapeutics Inc. - Common Stock Portage Biotech Flora Growth Ainos Talphera Citius Pharmaceuticals Gelteq NextCure Turnstone Biologics Aprea Therapeutics Qualigen Therapeutics (NASDAQ:QLGN) and Neuphoria Therapeutics Inc. - Common Stock (NASDAQ:NEUP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability. Is QLGN or NEUP more profitable? Company Net Margins Return on Equity Return on Assets Qualigen TherapeuticsN/A N/A -424.18% Neuphoria Therapeutics Inc. - Common Stock N/A N/A N/A Do insiders & institutionals believe in QLGN or NEUP? 3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics Inc. - Common Stock shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 0.7% of Neuphoria Therapeutics Inc. - Common Stock shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, QLGN or NEUP? Qualigen Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics Inc. - Common Stock has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Which has better earnings & valuation, QLGN or NEUP? Qualigen Therapeutics has higher revenue and earnings than Neuphoria Therapeutics Inc. - Common Stock. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQualigen Therapeutics$4.98M0.54-$13.42MN/AN/ANeuphoria Therapeutics Inc. - Common Stock$662.72K13.76-$15.49MN/AN/A Do analysts recommend QLGN or NEUP? Neuphoria Therapeutics Inc. - Common Stock has a consensus target price of $21.00, indicating a potential upside of 304.62%. Given Neuphoria Therapeutics Inc. - Common Stock's stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics Inc. - Common Stock is more favorable than Qualigen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Neuphoria Therapeutics Inc. - Common Stock 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer QLGN or NEUP? Qualigen Therapeutics received 6 more outperform votes than Neuphoria Therapeutics Inc. - Common Stock when rated by MarketBeat users. However, 100.00% of users gave Neuphoria Therapeutics Inc. - Common Stock an outperform vote while only 87.50% of users gave Qualigen Therapeutics an outperform vote. CompanyUnderperformOutperformQualigen TherapeuticsOutperform Votes787.50% Underperform Votes112.50%Neuphoria Therapeutics Inc. - Common StockOutperform Votes1100.00% Underperform VotesNo Votes Does the media favor QLGN or NEUP? In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 equaled Neuphoria Therapeutics Inc. - Common Stock'saverage media sentiment score. Company Overall Sentiment Qualigen Therapeutics Neutral Neuphoria Therapeutics Inc. - Common Stock Neutral SummaryNeuphoria Therapeutics Inc. - Common Stock beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks. Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QLGN vs. The Competition Export to ExcelMetricQualigen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.84M$6.59B$5.41B$7.70BDividend YieldN/A3.21%5.44%4.33%P/E RatioN/A7.0522.2318.31Price / Sales0.54273.45398.02107.04Price / CashN/A65.6738.2034.62Price / Book-0.186.506.824.25Net Income-$13.42M$142.50M$3.20B$247.51M7 Day Performance13.40%8.32%5.78%6.86%1 Month Performance11.08%-5.61%-4.31%-2.95%1 Year Performance-75.49%0.11%17.88%5.17% Qualigen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QLGNQualigen TherapeuticsN/A$3.51-3.6%N/A-76.4%$2.58M$4.98M0.0050NEUPNeuphoria Therapeutics Inc. - Common Stock1.1629 of 5 stars$5.17+4.4%$21.00+306.2%N/A$9.08M$662,715.000.00N/APRTGPortage Biotech0.2141 of 5 stars$8.88+3.4%N/A+85.3%$9.01MN/A-0.216FLGCFlora Growth1.9147 of 5 stars$0.46+0.7%$5.00+979.9%-62.6%$9.00M$59.51M-0.35280Gap UpAIMDAinos0.8981 of 5 stars$0.58-9.7%N/A-47.6%$8.92M$20,729.00-0.3540TLPHTalphera2.2422 of 5 stars$0.52+4.1%$4.33+732.5%-50.0%$8.90M$281,000.00-0.7519Positive NewsGap UpCTXRCitius Pharmaceuticals2.0768 of 5 stars$0.99+5.3%$54.50+5,406.2%-95.1%$8.80MN/A0.0020GELSGelteqN/A$0.93+13.4%N/AN/A$8.78MN/A0.00N/ALockup ExpirationNXTCNextCure4.2307 of 5 stars$0.31+7.2%$3.50+1,021.8%-70.9%$8.74MN/A-0.1590Upcoming EarningsGap UpHigh Trading VolumeTSBXTurnstone Biologics2.5648 of 5 stars$0.38-2.1%$0.45+19.4%-89.6%$8.72M$19.31M-0.1282APREAprea Therapeutics2.5329 of 5 stars$1.58+1.9%$15.50+881.0%-68.0%$8.68M$580,000.00-0.567Positive News Related Companies and Tools Related Companies NEUP Competitors PRTG Competitors FLGC Competitors AIMD Competitors TLPH Competitors CTXR Competitors GELS Competitors NXTC Competitors TSBX Competitors APRE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QLGN) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy QLGN Stock Free QLGN Stock Alerts